Many Halozyme Therapeutics, Inc.(HALO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Halozyme Therapeutics was Downgraded by Citigroup to Neutral on Jan 6, 2017.
Company has reported several Insider transactions to the SEC, on Aug 26, 2015, Laurie Stelzer (CFO) purchased 10,000 shares at 17.24 per share price.On Jun 22, 2015, Kenneth J Kelley (director) sold 20,000 shares at 21.00 per share price.
Halozyme Therapeutics Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $-0.26. The company had revenue of $31.90 million for the quarter, compared to analysts expectations of $33.82 million. The companys revenue was up 53.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.5 by 6 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. A sell rating was given by 1 analyst.
Halozyme Therapeutics, Inc. (NASDAQ:HALO): The mean short term price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been established at $14.15 per share. The higher price target estimate is at $20 and the lower price target estimate is expected at $7 according to 5 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $4.86
Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose 2.36% or 0.29 points on Tuesday and made its way into the gainers of the day. After trading began at $12.27 the stock was seen hitting $12.61 as a peak level and $12.045 as the lowest level. The stock ended up at $12.6. The daily volume was measured at 1,017,109 shares. The 52-week high of the share price is $14.38 and the 52-week low is $7.175. The company has a market cap of $1,632 million.
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The companys broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The companys initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozymes highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.